| Document |
Document Title |
|
WO/2010/066682A1 |
The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.
|
|
WO/2010/066100A1 |
The 2-oxo-1,3-oxaazocyclopentane-4-formamide derivatives of formula I, the geometrical isomers, the pharmaceutical salts or hydrates, the preparation method thereof, and the pharmaceutical compositions containing the said compounds. The ...
|
|
WO/2010/064189A1 |
The present invention provides a method for regeneration of chiral 2,2'-cyclopropylidene-bis(oxazolines), such as (3&R, 3'aR,8aS,8'aS )-2,2'-cyclopropylidenebis-[3a,8a]-dihydro-8H-indeno-[l,2-d]
-oxazole and (45,4'5,5R,5'R )-2,2'-cyclopr...
|
|
WO/2010/065512A2 |
The present invention is directed to compounds represented by structural formula (I), or a pharmaceutically acceptable salt or a transition metal chelate, coordinate or complex thereof or a transition metal chelate, coordinate or complex...
|
|
WO/2010/061366A1 |
A process for preparing bisoprolol comprises reacting oxazolidinone sulphonate with 4-hydroxybenzylaldehyde to form oxazolidinone benzaldehyde, forming oxazolidone benzylalcohol from oxazolidone benzaldehyde, and subsequently reacting ox...
|
|
WO/2010/058206A1 |
A method of making a phenylethylamine of formula (B): wherein R2, R3, R4, R5, R6, Rα, Rβ and Rn are each independently selected from hydrogen, alkyl, acyl, aryl, amido, amino acids, sugars and nucleotides. The method includes the reduc...
|
|
WO/2010/058995A1 |
Provided is an electroluminescent device comprising an organic layer interposed between an anode and a cathode on a substrate, wherein the organic layer includes an electroluminescent layer containing one or more dopant compound (s), and...
|
|
WO/2010/056585A2 |
Disclosed are compounds and compositions of the formula (I) as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula (I).
|
|
WO/2010/051935A2 |
The present invention relates to substituted amido phenoxybenzamide compounds of general formula (I) in which A, R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the claims, to pharmaceutical compositions and combinations conta...
|
|
WO/2010/054042A2 |
The present invention relates to new dimethylphenoxy inhibitors of viral protease or parasitic enzymes, pharmaceutical compositions thereof, and methods of use thereof. Formula (I)
|
|
WO/2010/050779A1 |
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells comprising the same. The organic electroluminescent compounds according to the present invention exhibit high luminou...
|
|
WO/2010/050445A1 |
A compound having an ACC inhibitory effect and useful for prevention/treatment of adiposis, diabetes, hypertension, hyperlipemia, heart failure, diabetic complication, metabolic syndrome, sarcopenia, cancer and the like. The compound ha...
|
|
WO/2010/050577A1 |
A compound having a strong analgesic action on both nociceptive pain and neuropathic pain with reduced side effects, and a pharmaceutical use of the compound. Specifically disclosed is a cyclohexane derivative typified by the formula, a ...
|
|
WO/2010/050461A1 |
A novel low molecular weight compound which inhibits the production of inducible MMPs, particularly MMP-9, rather than the production of constitutive MMP-2 is provided, and furthermore, a preventive/therapeutic agent for an autoimmune di...
|
|
WO/2010/048514A1 |
A method for forming an optionally substituted 2-aminobenzoxazole compound includes: contacting an optionally substituted 2-aminophenol compound with (1) an amine of the formula NHR2R3, wherein R2 and R3 are each independently selected f...
|
|
WO/2010/048207A2 |
Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
|
|
WO/2010/044054A1 |
The invention relates to novel phenethylamide derivatives and their heterocyclic analogues of formula (I), wherein A, B, R1, R2 and R3 are as described in the application, and to the use of such compounds, or of pharmaceutically acceptab...
|
|
WO/2010/044441A1 |
Disclosed is a compound useful as a vascular endothelial lipase inhibitor. Specifically disclosed is a pharmaceutical composition having an inhibitory activity on vascular endothelial lipase, which comprises a compound represented by for...
|
|
WO/2010/042475A1 |
In its many embodiments, the present invention provides a novel class of spiroaminooxazoline analogues as modulators of α2C adrenergic receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more suc...
|
|
WO/2010/042030A1 |
A compound of formula (I): N-oxides, addition salts, quaternary amines metal complexes stereochemically isomeric forms and metabolites thereof, wherein A is CR1 or N; D is H, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl or Q is C2-C6alkenyl, C...
|
|
WO/2010/041748A1 |
Disclosed is a prophylactic or therapeutic agent for diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cer...
|
|
WO/2010/042758A2 |
There are provided alpha helix scaffolds mimicking i, i+3/i+4, i+7 or i+11 residues having the general structure oxazole-pyridazine-piperidine or oxazole-pyridazine-oxazole. The common pyridazine heterocycle originates from substituted o...
|
|
WO/2010/042473A1 |
In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing...
|
|
WO/2010/039186A2 |
Compounds are disclosed that have formula I: wherein X, R1, R2, R3, R4 and n are as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals i...
|
|
WO/2010/039238A1 |
The invention relates to certain compounds according to Formula (I) : or pharmaceutically acceptable salts thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders a...
|
|
WO/2010/034236A1 |
A novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active N-acylbiphenyl alanine compounds, in particular neutral endopeptidase (NEP) inhibitors.
|
|
WO/2010/036905A1 |
The present invention provides benzoxazole compounds and pharmaceutically acceptable salts thereof and pharmaceutical compositions including the same. The present invention further provides methods of use as described herein.
|
|
WO/2010/034562A1 |
The invention relates to a method for producing heterocylces of the formula (I) by the catalytic reaction of an aromatic dinitrile of the formula using an amino alcohol, characterized in that the amino alcohol and the catalyst are provid...
|
|
WO/2010/036908A1 |
The present invention provides methods of preventing or treating malaria using benzoxazole compounds. The present invention further provides pharmaceutical compositions including an effective amount of the benzoxazole compounds for the p...
|
|
WO/2010/031835A2 |
The present invention relates to (R, S) 2-aryl-propionic acids and derivatives, their single enantiomer (S) and to pharmaceutical compositions containing them, which are used in the prevention and treatment of tissue damage due to the ex...
|
|
WO/2010/009405A9 |
Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The co...
|
|
WO/2010/031769A1 |
Comprising a preparation process of linezolid from a compound of formula (IV) where R1 is selected from a (C4-C-10)-alkyl radical which is attached to the N atom by a tertiary C atom, and a straight or branched (C3-C-10)-alkenyl radical ...
|
|
WO/2010/029379A1 |
The present invention relates to compounds of general formula (i) having an oxime moiety or a pharmaceutically acceptable salt, hydrate or solvate thereof and its use for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also know...
|
|
WO/2010/030891A2 |
The invention provides to a family of aryl guanidine-based F1F0-ATPase inhibitors, e.g., mitochondrial F1F0-ATPase inhibitors, methods for their discovery, and their use as therapeutic agents for treating certain disorders.
|
|
WO/2010/026365A1 |
The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.
|
|
WO/2010/025179A1 |
The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper ...
|
|
WO/2010/023892A1 |
Disclosed is a method of efficiently producing N-carboxy amino acid anhydride. The N-carboxy amino acid anhydride production method is characterized by including a process in which an amino acid organic salt compound and a carbonic acid ...
|
|
WO/2010/021693A2 |
The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.
|
|
WO/2010/020352A1 |
The invention provides compounds having utility inter alia as electron transport materials in optical light emitting diodes (OLEDs) and of the formula (I), (Il) or (III). Embodiments of the compounds when incorporated as electron transpo...
|
|
WO/2010/019830A1 |
Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provide...
|
|
WO/2010/019606A1 |
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorder...
|
|
WO/2010/018874A1 |
A compound having GPR52 agonist activity or a salt thereof is provided. The compound can be provided as a preventive / therapeutic agent for schizophrenia or the like. The compound is represented by the following formula (Ia): wherein A ...
|
|
WO/2010/015211A1 |
The present invention provides an improved process for preparing an oxazoline compound of the formula: (I) wherein R1 and R2 are independently hydrogen, sulfide, sulfoxide, sulfonyl, optionally substituted lower alkyl, optionally substit...
|
|
WO/2010/017079A1 |
The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active i...
|
|
WO/2010/014566A2 |
Processes for preparing oxazoline compounds are disclosed. These oxazoline compounds are useful intermediates in the preparation of Florfenicol and related compounds.
|
|
WO/2010/012794A1 |
The present invention relates to N-cycloalkyl-N-biphenylmethyl-carboxamide derivatives of formula (I) wherein A, Z1, Z2, Z3, X, n, Y and m represent various substituents, their process of preparation, preparation intermediate compounds, ...
|
|
WO/2010/012775A1 |
The present invention discloses novel and useful intermediates for the synthesis of ezetimibe (EZT), which intermediates share a characteristic Z-isomeric structure. Based on Z-5-(4-fluorophenyl)-pent-4-enoic acid, and proceeding the syn...
|
|
WO/2010/012107A1 |
The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods...
|
|
WO/2010/010435A2 |
The present invention provides fused oxazole and thiazole derivatives as TRPM8 (Transient Receptor Potential subfamily M, member 8) modulators. In particular, compounds described herein are useful for treating diseases, disorders, condit...
|
|
WO/2010/010014A1 |
The invention relates to compounds of formula(I) wherein R1 is hydrogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, halogen, cyano, nitro, hydroxy, C(O)O-lower alkyl, S(O)2-lower a...
|
